Patricia Ganz, MD, on Results from NSABP B-35: Patient-Reported Outcomes
2015 San Antonio Breast Cancer Symposium
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).
Sarat Chandarlapaty, MD, PhD
Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).
Judy E. Garber, MD, MPH
Judy E. Garber, MD, MPH, of the Dana-Farber Cancer Institute, gives her expert perspective on this vital and timely topic.
Clifford A. Hudis, MD, and Julia R. White, MD
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).
Andrew Seidman, MD, and Seema A. Khan, MD, MPH
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discuss the session moderated by Dr. Khan on this important topic (Session ES8).
Andrew Seidman, MD, and Erica L. Mayer, MD, MPH
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Erica L. Mayer, MD, MPH, of the Dana-Farber Cancer Institute, discuss this phase 3 trial of palbociclib with adjuvant endocrine therapy vs endocrine therapy alone for HR-positive/HER2-negative early breast cancer. (Abstract OT1-03-21)